High risk of bleeding (HBR) is a determining factor for the duration of dual antiplatelet therapy (DAPT). Recent studies have shown that the use of one-month DAPT is beneficial in terms of ischemic as well as hemorrhagic events, particularly in HBR patients, compared with longer DAPT. European guidelines therefore authorize one-month DAPT in HBR patients presenting even an acute coronary syndrome.

The HT Supreme Drug Coated Coronary Stent System (HT Supreme DES) is designed to promote reendothelialization as quickly as possible. That's why the stent is called "HT" Supreme, with "HT" standing for "Healing Targeted", enabling a DAPT of just 1 month in all-comers HBR patients.

Thanks to these features, the investigators aim to demonstrate ischemic and hemorrhagic complication rates lower than those found in the literature with other stent.

Inclusion Criteria:

• Patient aged ≥ 18 years
• Male or female patient requiring a coronary angioplasty procedure according to European recommendations,
• Patients undergoing revascularization with HT-supreme stents
• Patient at high risk of bleeding according to ARC HBR definition (9).
• Patient affiliated to or benefiting from a social security scheme
• Patient who does not object to research

Exclusion Criteria:

• Estimated lifespan <1 year,
• Allergy and any other contraindication to aspirin and/or clopidogrel listed in the summary of product characteristics,
• Allergy to iodinated contrast media
• Adults under legal protection (guardianship, curatorship or safeguard of justice).
• Persons deprived of their liberty by judicial or administrative decision,
• Patient in a period of relative exclusion from another research protocol,

Patients scheduled for coronary angiography and meeting the inclusion criteria will be recruited in the cardiology departments of participating centers.